GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Total Inventories

Knight Therapeutics (TSX:GUD) Total Inventories : C$95.4 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Total Inventories?

Knight Therapeutics's total inventories for the quarter that ended in Mar. 2024 was C$95.4 Mil. Knight Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was C$93.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Knight Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was C$0.97.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Knight Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 190.24.

Inventory Turnover measures how fast the company turns over its inventory within a year. Knight Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.48.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Knight Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.08.


Knight Therapeutics Total Inventories Historical Data

The historical data trend for Knight Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Total Inventories Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.87 56.51 72.40 92.49 91.83

Knight Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.99 98.68 112.45 91.83 95.40

Knight Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Knight Therapeutics  (TSX:GUD) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Knight Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(192.254+0.75 * 85.963+0.5 * 95.4-206.316
-0-0)/101.187
=0.97

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Knight Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=93.617/44.905*365 / 4
=190.24

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Knight Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=44.905 / 93.617
=0.48

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Knight Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=93.617 / 86.604
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Knight Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines